Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 161
• PD-1 157
• KRAS 97
• ALK 72
• TP53 10
• HER2 61
• MET 43
• STAT3 0
• PI3K 1
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 12
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• HDAC 0
• EZH2 2
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CXCR4 1
• CD47 1
• CDK4/6 4
• METTL3 0
• NLRP3 0
• HSP90 0
• SHP2 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Updated 13 Aug 2026

  “Accrual and drug manufacturing and supply were discontinued in 2025.”Registry text, quoted unchanged. Source

• Terminated

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Updated 9 Apr 2026

  “Sponsor discontinued the trial”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· AstraZeneca· Source

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Source

• PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

  NCT04209595· National Cancer Institute (NCI)· Source

• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Source

• A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

  NCT04826341· National Cancer Institute (NCI)· Source

• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

  NCT04380636· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 313
• Sequence Analysis, RNA 42
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 66
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 190
• Liquid Biopsy 76
• Circulating Tumor DNA 82
• Xenograft Model Antitumor Assays 615
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 288
• Deep Learning 209
• Cohort Studies 288
• Genome-Wide Association Study 75

• Machine learning prognostic model and drug survival analysis for lung adenocarcinoma in the context of radiotherapy.

  Pak J Pharm Sci, Dec 2026

• Integrating Machine Learning to Identify Prognostic Subtypes and the Cisplatin Resistance Gene RRM2 in Lung Adenocarcinoma.

  Thorac Cancer, Nov 2026

• Machine learning-assisted Ti3C2Tx MXene/Au@Fe3O4 core-shell nanocomposite-based electrochemical genosensor for ultrasensitive detection of EGFR T790M mutation in lung cancer.

  Mikrochim Acta, Oct 2026

• Differential Diagnosis of Early-Stage Pulmonary Sarcoidosis With Normal Serum Angiotensin-Converting Enzyme Activity Using Peripheral Blood Indicators: Machine Learning Models Development and Validation.

  JMIR Med Inform, Oct 2026

• Machine learning-derived intracellular protein-based prognostic model reflecting a senescence-associated secretory phenotype-driven immunosuppressive microenvironment in lung adenocarcinoma.

  PeerJ, Oct 2026

• Predicting lymph node metastasis in non-small cell lung cancer using clinical and PET/CT-derived morphological features: An interpretable machine-learning study.

  PLoS One, Oct 2026

• Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

  J Vis Exp, Oct 2026

• Predicting miRNA-Disease Associations Based on Contrastive Learning of Linear and Nonlinear Features.

  Genes (Basel), Oct 2026

• Integrated multi-omics, network pharmacology, and machine learning reveal the active constituents and pharmacological mechanism of Fufang E'jiao Jiang against lung cancer-related fatigue.

  Anal Chim Acta, Oct 2026

• Radiomics machine learning models for lung cancer early diagnosis in heterogenous multicentre chest CT data: LIBRA study results.

  Eur Radiol Exp, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.